You want the CRO to do a thorough job. Psoriasis can be more difficult to properly classify the results than other types of trials. For example the clinical site classifies the improvement as no change from moderate the CRO questions it looks like an improvement to mild Dr. did you mix this up with another patient and so on. Some may classify a complete remission from severe to mild even though there are no more signs of psoriasis. Why because they never had that happen before, so they will think that’s the more accurate diagnosis. Even though the trial protocols clearly say how they should be classified. I’m not joking. And the more sites you have the more problems. When Leo added sites to speed the trial up, I cringed, because you save time on the front end, but it can significantly increase it on the back end.
(3)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links